Clinical Trial

Phase 2, Efficacy and Safety Study of ACP-204 in Lewy Body Dementia Psychosis

Name: Phase 2, Efficacy and Safety Study of ACP-204 in Lewy Body Dementia Psychosis — clinical trial record (NCT07029581)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

Multicenter, randomized, 6-week, double-blind, placebo-controlled, parallel-group, Phase 2 study in subjects with LBDP.

Protocol Amendment History 14 amendments

This ClinicalTrials.gov record has been amended 14 times since 2025-06-12; most recent amendment 2026-07-23.

Status change: Not Yet Recruiting → Recruiting 2025-07-16

Trial Details

NCT Number	NCT07029581
Lead Sponsor	ACADIA Pharmaceuticals Inc.
Conditions	Lewy Body Dementia Psychosis
Enrollment	180 participants
Start Date	2025-08-06
Primary Completion	2028-02 (estimated)
Study Completion	2028-03 (estimated)
Updated on ClinicalTrials.gov	2026-07-24